Pharmafile Logo

News and Press Releases

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD

Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adults with elevated eosinophils Approval marks the first new treatment...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: March 28, 2025

Sanofi
One Onslow Street, Guildford, Surrey, GU1 4YS, UK

Exclusive UniSafe® distribution agreement between Owen Mumford and NIPRO exceeds expectations in Japan with new biosimilar launch

6 December 2024 - Oxford, UK – Owen Mumford, a global leader in medical devices, is pleased to announce that its exclusive agreement with Osaka-based NIPRO CORPORATION (NIPRO) to distribute...

Category: Drug Delivery, Manufacturing and Packing
Posted: December 6, 2024

Owen Mumford Pharmaceutical Services
info@owenmumford.com
Brook Hill Woodstock Oxfordshire OX20 1TU

ERS Genomics and Université de Montréal sign CRISPR/Cas9 license agreement

License agreement provides Université de Montréal access to CRISPR gene editing technology for use across its platform services 1 October 2024 -- Dublin, Ireland, and Montreal, Canada -- ERS Genomics...

Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: October 1, 2024

ERS Genomics
8th Floor, Block E, Iveagh Court, Harcourt Road, Dublin D02 YT22, Ireland

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old

Recommendation based on a phase 3 study showing a significantly greater proportion of children on Dupixent achieved histological remission, compared to placebo, consistent with improvements seen in adults and adolescents...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 20, 2024

Regeneron
ukinfo@regeneron.com
The Charter Building, Vine Street, Uxbridge, Middlesex, United Kingdom, UB8 1JG

Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer

Results from the pivotal Phase III ARANOTE trial evaluating darolutamide plus androgen deprivation therapy (ADT) showed a statistically significant increase in radiological progression-free survival (rPFS) compared to placebo plus ADT...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 16, 2024

Orion
Orion Corporation Orionintie 1A, FI-02200 Espoo P.O.Box 65, FI-02101 Espoo

Just – Evotec Biologics expands tech partnership for biosimilars with Sandoz

Just – Evotec Biologics expands partnership with Sandoz for development and commercial manufacturing of biosimilars Additional biosimilars potentially to be added to Sandoz development pipeline Further guarantees for Sandoz long-term...

Category: BioManufacturing, Biotechnology
Posted: July 10, 2024

Just – Evotec Biologics
info@evotec.com
Just – Evotec Biologics, Inc. 401 Terry Avenue North Seattle, WA 98109, US

Formycon receives FDA approval for FYB203/ AHZANTIVE) (aflibercept-mrbb), a biosimilar to Eylea

1 July 2024, Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) and its licencing partnerKlinge Biopharma GmbH ("Klinge") jointly announce that the U.S. Food and Drug Administration ("FDA")approved FYB203/AHZANTIVE (aflibercept-mrbb),...

Category: Pharmaceutical
Posted: July 1, 2024

Formycon
inof@formycon.com
Formycon AG, Fraunhoferstraße 15, 82152 Martinsried/Planegg, Germany

Formycon reports on the results of the annual general meeting

Management provides detailed report on financial year 2023 and current company performance. Shareholders approve all agenda items and formally approve the acts of the members of the management board and...

Category: BioManufacturing
Posted: June 13, 2024

Formycon
inof@formycon.com
Formycon AG, Fraunhoferstraße 15, 82152 Martinsried/Planegg, Germany

Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries in Europe

30 November 2023 -- Bengaluru, India -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, today announced that the integration of the Viatris’ biosimilars business in 31 European countries has been successfully...

Category: Pharmaceutical
Posted: November 30, 2023

Biocon Biologics
contact@bioconbiologics.com
Biocon House, Semicon Park Electronics City, Phase – II, Hosur Road Bengaluru 560100, Karnataka, India

AskBio Announces First Patient Dosed in Phase 1/Phase 2 Trial of AB-1003 Gene Therapy for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

Gene therapy developed to restore FKRP enzyme activity, primarily inside muscle cells, for the treatment of LGMD2I/R9 3 August 2023 -- North Carolina, US -- Asklepios BioPharmaceutical, Inc. (AskBio), a...

Category: Clinical Trials
Posted: August 3, 2023

AskBio
corpcommunications@askbio.com.
Roslin Innovation Centre Easter Bush Campus Edinburgh, Scotland EH25 9RG